Generate:Biomedicines to Present Phase 1 Results for AI-Engineered GB-0895 in Asthma at the European Respiratory Society International Congress
Generate Biomedicines official news-release RSS · Indexed industry source record · Source published: Thu Sep 25 2025 11:00:00 GMT+0000 (Coordinated Universal Time) · Indexed here: Thu Oct 08 2026 09:07:27 GMT+0000 (Coordinated Universal Time)
Saved source excerpt
GB-0895, a next-generation, ultra-high affinity anti-TSLP monoclonal antibody, demonstrated prolonged half-life and sustained pharmacology in asthma patients GB-0895 is optimized for a single subcutaneous injection every six months Somerville, Mass., September 25, 2025 — Generate:Biomedicines (“Generate”) today announced that results from its Phase 1 study of GB-0895 will be presented as a late-br
This is a cited excerpt from the source. Read the original link for the complete text. Automated indexing and topic classification do not constitute fact verification.